Journal
CANCER BIOLOGY & THERAPY
Volume 10, Issue 12, Pages 1219-1223Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.10.12.13450
Keywords
polyi-c; signaling pathway; tumor immunotherapy; TLR3; RIG-I; MDA-5; apoptosis
Categories
Funding
- Science and Technology Department of Zhejiang Province [2010R10080]
- Health Bureau of Zhejiang Province, China [2008QN016]
- Zhejiang University
Ask authors/readers for more resources
Polyinosinic-polycytidylic acid (polyi:c) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor (TLR) 3 and retinoic acid inducible gene I (RIG-I)-like receptors (RLRs), including RIG-I and melanoma differentiation-associated gene 5 (MDA5). The effect of polyi:c on tumor immunotherapy has been well explored for several decades. The accumulated evidence suggests that polyi:c could be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Recent studies have also shown that activation of TLR3 and RLR signaling by polyi:c can directly trigger apoptosis in some cancer cells. This review focuses on polyi:c-induced signaling pathways and the applications of polyi:c in cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available